Single-molecule detections at point-of-care: is this a dream?

Research news

Single-molecule detections at point-of-care: is this a dream?

23 Jan, 2025

Join Luisa Torsi as she discusses single-molecule detections at point-of-care during her webinar.

  • Webinar date: 13 February
  • Time: 7-8 PM GMT
  • Presented by: Luisa Torsi
  • Sign up HERE>>

Imagine a future where diseases can be detected at their earliest stages, even before symptoms appear.

This is no longer a dream but a revolutionary step forward in healthcare. And it's made possible by the groundbreaking SiMoT (Single-Molecule-with-a-large-Transistor) bioelectronic platform.

Join us for this insightful webinar to discover how this technology is set to transform diagnostics.

A new era in early disease detection

Detecting diseases in asymptomatic individuals is a game-changer. It enables timely interventions and significantly improving patient outcomes.

The SiMoT platform aligns with the World Health Organization’s benchmarks for point-of-care testing (POCT), offering unparalleled sensitivity and specificity in a portable, cost-effective format.

As part of the SiMBiT project, SiMoT is capable of detecting both protein and DNA single markers in just 0.1 mL of biological fluid.

This level of precision makes it an ideal tool for early disease screening, even in individuals showing no symptoms.

Unmatched diagnostic performance

SiMoT offers diagnostic accuracy on par with molecular tests, achieving an impressive 96-99% sensitivity and specificity.

This exceptional performance was demonstrated in a pre-clinical trial for pancreatic cancer. No false negatives were reported among more than 70 patients.

Such results highlight the potential of SiMoT to revolutionize early disease detection.

Real-world applications and clinical trials

The SiMoT platform is undergoing rigorous evaluation in an in-vivo diagnostic clinical trial involving 1,500 assays of blood and urine samples from oncology patients.

This trial aims to advance the technology from TRL5 to TRL7, bringing it closer to widespread clinical adoption.

Additionally, the SiMBiT project’s development of a 96-bioelectronic sensor array for multiplexed detection has been validated in clinical trials for early cancer screening, further demonstrating its potential.

Key learnings from the webinar

By attending this webinar, you will:

  • Discover early detection capabilities
  • Explore diagnostic precision
  • Gain SiMBiT project insights
  • Shape the future of healthcare.

Why attend?

This webinar is your chance to learn from one of the leading minds in the field, Luisa Torsi.

You will gain insights into a technology that promises to redefine diagnostic capabilities.

Whether you’re a healthcare professional, researcher, or simply interested in cutting-edge innovations, this session is not to be missed.

Sign up now

Don’t miss this opportunity to be part of a transformative discussion on the future of healthcare.

Secure your spot NOW>>

ILM Guide 2026/27

Explore our Digital Edition

Discover the latest news and research

Digital edition

Explore Our Other Sites

Envirotech Online
EU ETS benchmark update puts industrial emissions data under sharper scrutiny
Explore more Arrow
Pollution Solutions Online
Next-generation reverse osmosis membranes for more efficient and cost-effective seawater desalination
Explore more Arrow
Petro Online
From specification to certification: Ensuring jet fuel conformity with reliable flash point testing
Explore more Arrow
Chromatography Today
Non-invasive flowmeters for real-time monitoring
Explore more Arrow